John R. Burnett
-
- Diabetes, Cardiovascular Risks, and Lipoproteins 51
- Clinical Biochemistry top 0.5%
- Metabolism and Genetic Disorders 12
- Surgery top 1%
- Lipoproteins and Cardiovascular Health 83
- Cholesterol and Lipid Metabolism 19
- Cancer Research top 2%
- Cancer, Lipids, and Metabolism 22
-
- Lipid metabolism and disorders 41
-
- Drug Transport and Resistance Mechanisms 11
-
- Peroxisome Proliferator-Activated Receptors 10
- Co-authors
- Amanda J. HooperGerald F. WattsFrank M. van BockxmeerP. Hugh R. BarrettDamon A. BellMurray W. HuffRobin WilliamsCyril Mamotte
- Partner nations
- AustraliaCanadaUnited States
In The Last Decade
John R. Burnett
158 papers receiving 4.4k citations
Peers
Comparison fields: 5 of 142
- Endocrinology, Diabetes and Metabolism 1.3k
- Clinical Biochemistry 463
- Surgery 2.5k
- Cancer Research 694
- Cardiology and Cardiovascular Medicine 956
Countries citing papers authored by John R. Burnett
This map shows the geographic impact of John R. Burnett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John R. Burnett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John R. Burnett more than expected).
Fields of papers citing papers by John R. Burnett
This network shows the impact of papers produced by John R. Burnett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John R. Burnett. The network helps show where John R. Burnett may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John R. Burnett, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 12 | |
| 2 | 2023 | 5 | |
| 3 | 2022 | 3 | |
| 4 | 2020 | 1 | |
| 5 | 2020 | 11 | |
| 6 | 2016 | 21 | |
| 7 | 2015 | 240 | |
| 8 | 2014 | 41 | |
| 9 | 2012 | 17 | |
| 10 | 2011 | 112 | |
| 11 | 2009 | 20 | |
| 12 | 2008 | 16 | |
| 13 | Drug profile: Sapropterin dihydrocholoride (Kuvan/Phenoptin), an orally active synthetic form of BH4 for the treatment og phenylketonuria | 2007 | 11 |
| 14 | 2007 | 147 | |
| 15 | A novel non-truncating ApoB gene mutation, R463W, causes familial hypobetalipoproteinemia | 2002 | 1 |
| 16 | 2001 | 24 | |
| 17 | Therapeutic efficiency of tirofiban in acute coronary syndromes (multiple letters) | 2000 | 3 |
| 18 | 1998 | 25 | |
| 19 | 1997 | 91 | |
| 20 | 1988 | 23 |
About John R. Burnett
John R. Burnett is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Cardiology and Cardiovascular Medicine, having authored 164 papers that have together received 4.6k indexed citations. Recurring topics across this work include Lipoproteins and Cardiovascular Health (83 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (51 papers), Lipid metabolism and disorders (41 papers), Cancer, Lipids, and Metabolism (22 papers), Cholesterol and Lipid Metabolism (19 papers), Metabolism and Genetic Disorders (12 papers), Drug Transport and Resistance Mechanisms (11 papers) and Peroxisome Proliferator-Activated Receptors (10 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (1.3k citations), Clinical Biochemistry (463 citations) and Surgery (2.5k citations). John R. Burnett has collaborated with scholars based in Australia, Canada and United States. Frequent co-authors include Amanda J. Hooper, Gerald F. Watts, Frank M. van Bockxmeer, P. Hugh R. Barrett, Damon A. Bell, Murray W. Huff, Robin Williams, Cyril Mamotte, A. David Marais and Donald Moshen Tanyanyiwa. Their work appears in journals such as The Lancet, Journal of Biological Chemistry and Circulation.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.